The discovery of drugs from marine natural products has witnessed a significant resurgence in recent years. A diverse range of marine organisms, including cone snails, bacteria, cyanobacteria, fungi, and halophytes, have yielded valuable compounds for drug development. These organisms contribute over 90% of the oceanic biomass, offering unique chemical properties with great potential, particularly in the field of anticancer research. The review highlights the historical successes in marine natural product-based drug discovery, emphasizing their novel chemical structures and bioactive properties. It sheds light on critical factors contributing to these discoveries, such as interdisciplinary collaborations between marine biologists, chemists, and pharmacologists, advanced isolation and characterization techniques, and the understanding of marine ecological niches. Challenges include limited supply, environmental concerns, and the complexity of chemical synthesis. Translating marine-derived compounds into viable pharmaceuticals requires rigorous testing, preclinical studies, and clinical trials. Looking forward, advances in research and technology, such as metagenomics and synthetic biology, offer promising avenues for faster and more efficient discovery and development of marine-derived drugs. The potential for uncovering new therapeutic agents remains vast, and the continued exploration of marine natural products holds the promise of significant breakthroughs in drug development while considering sustainable practices and environmental concerns.
Read full abstract